{"id":"anx007","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reactions"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ANX007 works by binding to and neutralizing amyloid-beta oligomers, which are toxic aggregates of amyloid-beta peptides that contribute to the progression of Alzheimer's disease. By reducing the levels of these oligomers, ANX007 aims to slow down or halt the disease's progression. This mechanism is thought to be key in the development of ANX007 as a potential therapeutic agent for Alzheimer's disease.","oneSentence":"ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:10:50.893Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Alzheimer's disease"}]},"trialDetails":[{"nctId":"NCT06510816","phase":"PHASE3","title":"A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Annexon, Inc.","startDate":"2024-07-30","conditions":"Geographic Atrophy","enrollment":659},{"nctId":"NCT04656561","phase":"PHASE2","title":"A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy","status":"COMPLETED","sponsor":"Annexon, Inc.","startDate":"2021-02-26","conditions":"Geographic Atrophy","enrollment":270},{"nctId":"NCT04188015","phase":"PHASE1","title":"Study of ANX007 in Participants With Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Annexon, Inc.","startDate":"2018-07-25","conditions":"Open Angle Glaucoma","enrollment":17},{"nctId":"NCT03488550","phase":"PHASE1","title":"Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Annexon, Inc.","startDate":"2018-03-23","conditions":"Open-angle Glaucoma","enrollment":9}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ANX007","genericName":"ANX007","companyName":"Annexon, Inc.","companyId":"annexon-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ANX007 is an anti-Aβ oligomer antibody targeting the aggregation of amyloid-beta oligomers in the brain. Used for Alzheimer's disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}